Washed human platelets bound radioiodinated low density lipoprotein ( 125 I-LDL) to a class of saturable binding sites; they numbered 1,348±126 per platelet, and the dissociation constant (K D ) was 50.7±9 nM.
LDL Binding Sites on Platelets Differ From the "Classical" Receptor of Nucleated Cells
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I-LDL binding to platelets was reversible, and apparent equilibrium was attained within 25 minutes at 22°C and was characterized by forward and reverse rate constants of 1.47xlO 4 Xsec"'xM" 1 and 8xlO~4xsec~' xM" 1 , respectively. Such binding was largely unaltered by temperature, divalent ions, and chelating agents. In addition, neither did receptor regulation (up or down) occur when platelets were loaded with cholesterol, nor did prostaglandin E, (PGE,) increase the binding of 12S I-LDL to platelets. On the other hand, the specificity of LDL binding was not typical of the LDL receptor of nucleated cells. Lipoproteins competed for the occupancy of LDL binding sites in platelets with the following order of potency: very low density >> intermediate density > high density subfraction 2. High density lipoprotein subfraction 3, heparin, and PGE, had no effect on this binding. I-LDL by lymphocytes was inhibited by the monoclonal antibody IgG-C7 directed against the LDL receptor to 88%, 85%, and 85% (p<0.001), respectively. However, with this monoclonal antibody, a blocking effect on neither 125 I-LDL binding to platelets nor on LDL-enhanced platelet aggregation induced by ADP and collagen was found. Moreover, we confirmed the existence of LDL binding in platelets from patients with familial hypercholesterolemia. Our results indicate that human platelets bind LDL by saturable sites, which clearly differ from the "classical" LDL receptor in their binding properties, absence of receptor regulation, presence in platelets of familial hypercholesterolemia patients, and the lack of a blocking effect of IgG-C7 on LDL binding and LDL biological activity. vealed that plasma lipoproteins can modulate the reactivity of isolated human blood platelets. 1 -3 Platelet-rich plasma (PRP) from patients with familial hypercholesterolemia (FH) has been reported to be hyperresponsive to certain aggregating stimuli 4 -6 and to produce increased amounts of thromboxane A 2 when activated. 78 When platelets are separated from their plasma environment and incubated with physiological and supraphysiological concentrations of isolated low density lipoprotein (LDL; 0.5-2 g of protein per liter), they become rapidly sensitized; at higher concentra-tions, LDL has been shown to cause platelet aggregation by itself. 9 Specific LDL binding to isolated platelets has been reported by several authors. 10 - 15 Such binding could be the initial step in the modulation process. 1617 However, there are disagreements about the properties of these binding sites (number of binding sites per platelet, their dependence on temperature, the effect of divalent ions, the time required for reaching apparent equilibrium, and the specificity of interaction between lipoproteins and platelets). Postbinding events also remain unclear, but some evidence suggests that LDL binding to platelets promotes phosphatidylinositol hydrolysis, with the phosphorylation of a 47-kd protein. 16 Since the first descriptions of the existence of specific, high-affinity, and saturable binding sites for LDL in platelets were given, some evidence has been presented that indicates that these sites could be different from the "classical" LDL receptor of nucleated cells. Recently, both Koller et al 18 and Hassall et al 15 have purified an LDL binding protein from human platelet membranes of an apparent molecular mass of 140 kd. In addition, a high density lipoprotein 3 (HDL3) binding protein with an apparent molecular mass of 114 kd has been isolated from platelet membranes, 18 suggesting that LDL and HDL, binding proteins could be related to the fibrinogen receptor (the glycoprotein Hb-IIIa complex) or even could be the same.
In the present study we examined the differences between the LDL receptor of nucleated cells (fibroblasts and lymphocytes) and the LDL binding sites on platelets by evaluating the properties of LDL binding to washed human platelets. In addition, to confirm these differences we used the monoclonal antibody against the LDL receptor (immunoglobulin G [IgG] C7), which recognizes the first cysteine-rich repeat in the ligandbinding domain of the LDL receptor, 19 to study their blocking ability on 125 I-LDL binding to platelets and LDL platelet sensitization.
Methods

Materials
Sucrose and EDTA were purchased from E. Merck (Darmstadt, FRG); bovine serum albumin (BSA) and human serum albumin (HSA) were from Fluka Chemie/AG (Basel, Switzerland); Iodo-Gen, cloramphenicol, prostaglandin E! (PGE^, cholesterol, heparin, and aprotinin were from Sigma Chemical Co. (St. Louis, Mo.); and Sephadex PD-10 columns and Ficoll-Paque were from Pharmacia LKB (Uppsala, Sweden). The purified IgG 2 b murine monoclonal antibody, clone C7 (IgG-C7), directed against the first cysteine-rich repeat in the ligand-binding domain of the LDL receptor, 19 was from Amersham Iberica (Madrid, Spain); culture media (RPMI-1640 and minimal essential medium [MEM]), fetal calf serum (FCS), penicillin, and streptomycin were from Flow Labs (Irvine, Scotland); plastic culture dishes and flasks were from Costar (Badhoevedorp, The Netherlands); and Na 125 I was from New England Nuclear (Boston, Mass.).
Lipoprotein Preparation
Human plasma lipoproteins (very low density lipoprotein [VLDL], d< 1.006 g/ml; intermediate density lipoprotein [IDL] , d= 1.006-1.019 g/ml; LDL, d= 1.019-1.063 g/ml; HDL 2 , ^=1.063-1.125 g/ml; and HDL3, d= 1.125-1.210 g/ml) and lipoprotein-deficient serum (LPDS, d> 1.210 g/ml) were obtained from pooled sera of normolipidemic blood donors and isolated by sequential ultracentrifugation 20 in a Centrikon T 2060 ultracentrifuge (Kontron Instruments, Milano, Italy). Lipoproteins were washed during flotation with a potassium bromide solution of the respective lipoprotein density. The lipoproteins were exhaustively dialyzed against phosphate-buffered saline (PBS), pH 7.4, containing 10 mM EDTA. The concentration of lipoproteins was expressed in terms of protein content, as determined by the method of Bradford, 21 with BSA as the standard. The apoprotein (apo) composition of each lipoprotein class was routinely assessed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. The specific mobility of each lipoprotein was confirmed by acrylamideagarose gel electrophoresis.
lodination of Lipoproteins
Freshly isolated LDL from a pool of normolipidemic blood donor serum was labeled with 125 I by the IodoGen method. 22 Unbound iodine was removed by chromatography with a Sephadex PD-10 column previously equilibrated with PBS buffer, pH 7.4, containing 10 mM EDTA. The protein fractions were pooled and dialyzed against the same buffer for 24 hours and used immediately. Final specific radioactivity was 2±0.2 Bq/ng protein. In all cases, labeling efficiencies >80% were achieved, and <10% and <8% of the total radioactivity in the final preparation was due to free iodide (quantified as trichloroacetic acid-soluble radioactivity) and chloroform/methanol-extractable lipids, respectively. For comparative experiments (platelets, lymphocytes, and fibroblasts), the same batch of 125 I-LDL was used. The purity of labeled LDL was assessed by gel filtration in a fast protein liquid chromatography device (Pharmacia LKB). Labeled LDL (100 fig) was loaded onto a Superose 6 column; equilibrated with 0.15 mM NaCl, 1 mM EDTA, and 0.5 g/1 NaN 3 , pH 8; and developed at 0.5 ml/hr. Fractions (0.25 ml) were collected and counted on a gamma counter. A comparison of the chromatographic profiles of LDL before and after iodination strongly indicated that Iodo-Gen iodination itself did not cause aggregation or breakdown products of LDL.
Platelet Isolation and Binding Studies
Platelets were isolated from seven fresh platelet concentrates from controls provided by the blood bank of our hospital, from 40 ml citrated (sodium citrate 3.8%) blood from six healthy volunteers, and from patients with FH who have a partial (heterozygous, n=3) or total (homozygous, n = \) lack of LDL receptors on their nucleated cells. 23 All patients gave informed consent. Processing was started in the laboratory within 2 hours of whole-blood collection, and all procedures were carried out at room temperature. The PRP from individual control subjects and patients was obtained by centrifugation at 300g for 10 minutes. Aliquots of fresh platelet concentrates and PRP were centrifuged at 200g for 10 minutes to remove any contaminating erythrocytes. Then EDTA (5.6 mM) was added to the PRP, and the platelets were sedimented at 900g for 6 minutes. In some cases and especially when the platelets were to be used for platelet aggregation studies (see below), PGE, (5.6 /J.M) was also added to the PRP to prevent initial platelet activation. Then the platelet pellet was resuspended as previously described 24 I-LDL binding (0.05 g/1) in the presence of different concentrations and types of unlabeled lipoproteins, heparin, PGEi, and other proteins was assessed and measured as described above. Dissociation constants (K D ) for the competing ligands (micrograms of protein per milliliter) were determined according to the method of Cheng and Prusoff. 25 Displacement curves were also analyzed by Hill plots by following the method reported by Bennett and Yamamura. 26 To analyze the possible blocking effect of IgG-C7 on 125 I-LDL binding to platelets, we used the same experimental conditions described for lymphocytes (see below). Briefly, 10 8 platelets were preincubated with different concentrations of IgG-C7 (up to 150 mg/1) for 10 minutes at room temperature before the addition of 125 I-LDL (0.05 g/1), and the specific binding was then determined.
Calculation of the bound lipoprotein was based on the specific activity of the labeled ligand, and the results were expressed as nanograms of protein bound per 10 8 platelets. The specific binding was evaluated mathematically by Scatchard analysis 27 to determine the number of binding sites and the dissociation constant by using the KINETIC/EBDA/LIGAND program. 28 
Modulation of LDL Binding to Platelets After Cholesterol Enrichment
A modification of the procedure of Stuart et al 29 was used to load platelets with cholesterol. Briefly, within 40 minutes of collection PRP was adjusted to a platelet count of 10 9 /ml with incubation buffer, and 10 8 platelets (0.1 ml) were then incubated either with an ethanolic solution of nonlipoprotein cholesterol at a final concentration of 500 or 1,000 £ig/ml in the incubation medium or with ethanol alone (control). The mixtures were incubated for 5 hours at 37°C with gentle inversion of the incubation tubes every 30 minutes. After that the binding of 125 I-LDL to cholesterol-loaded and control platelets was measured as above. Platelet cholesterol was determined as previously described. 30 
Aggregation Studies
Blood with 3.8% sodium citrate was collected from healthy volunteers who had not taken any drugs for the previous 10 days. PRP was obtained by centrifugation at 200g for 10 minutes at room temperature. EDTA (5.6 /xM) and PGE, (5.6 fiM) were added to the PRP to prevent initial platelet activation, and the PRP was further centrifuged at 900g for 6 minutes. The platelet pellet was washed as previously described 24 in a volume of buffer (0.15 M NaCl, 20 mM Tris, 5 mM glucose, and 1 mM EDTA; pH 7.4) equal to that of the discarded plasma and centrifuged at 900g for 6 minutes. The washed platelets were resuspended at counts in the range 3-5xlO'7l in Tyrode's buffer (0.14 M NaCl, 2.7 mM KC1, 1 mM CaCI 2 , 12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 5.5 mM glucose, 3.5 mg/ml BSA, and 10 mM JV-2-hydroxyethylpiperazine-./V'-2-ethanesulfonic acid [HEPES]; pH 7.4). Platelets that were washed and resuspended in this manner showed "swirling" as a gross indication of maintenance of discoid shape and were fully responsive to weak agonists in the presence of fibrinogen for at least 1 hour. Platelet aggregation was performed as previously described 31 in a four-channel aggregometer (Aggrecorder II, model PA 3220, Menarini, Barcelona, Spain). Washed platelets (0.4 ml) with added fibrinogen (600 nM) were stimulated in the aggregometer cuvette at 37°C with the selected minimal concentrations of ADP (0.5-2 /xM) or collagen (0.5-1 /xg/ml) that produced a 30-60% or a 40-60% change in light transmittance, respectively, within 5 minutes of the addition of the stimulating agent. Platelet aggregation induced by a combination of 0.5 g/1 LDL and ADP or collagen was performed by incubating platelets for 5 minutes at 37°C with LDL or with buffer, following by addition of ADP or collagen to trigger the aggregation. The blank samples included Tyrode's buffer, fibrinogen, and LDL or saline. The effect of IgG-C7 on LDLinduced platelet reactivity was assessed by preincubation of platelets with the antibody (150 mg/1) at various periods of time and temperature (10 and 30 minutes at 4°C, 22°C, and 37°C) before the addition of LDL and ADP or collagen. Platelet aggregation was determined as above.
Lymphocyte Isolation and Binding Studies
Lymphocytes from blood (40 ml) of healthy volunteers, drawn into EDTA-containing (15%) Vacutainer tubes, were isolated by a flotation gradient in FicollPaque (d= 1.077 g/ml). The lymphocyte and monocyte layer was collected under sterile conditions and rinsed twice with PBS buffer, pH 7.4. The lymphocyte and monocyte pellet was resuspended in a cholesterol-deficient medium (RPMI-1640 containing 10% LPDS) and incubated for 2 hours at 37°C in a 5% CO 2 incubator to sediment the cells. Sedimented nonadherent lymphocytes were incubated for an additional 67 hours in the same medium. Then the lymphocytes (8x 10 6 in 0.25 ml) were preincubated for a previously selected time (10 minutes) at room temperature with or without (0.35 mg/1) IgG-C7 in a final volume of 0.3 ml of a cholesteroldeficient medium. After incubation, the medium was removed by centrifugation for 10 minutes at 2,000g, and the cells were incubated again for 2 hours with 1 ml ice-cold MEM containing 10% LPDS and 125 I-LDL (0.01 g of protein per liter). Nonspecific binding was determined in the presence of a 20-fold excess of unlabeled LDL. After incubation, 0.7-ml aliquots were removed and layered onto 0.8 ml of 20% sucrose in PBS buffer, pH 7.4, and centrifuged at room temperature for 3 minutes at 16,000g; the pellet was later recovered as described for the platelet pellet.
LDL Receptor Activity in Lymphocytes
Proteolytic degradation of I-labeled, soluble (noniodide) material formed by the cells and released into the medium was determined by the procedure described by Bierman et al. 33 Nonspecific binding was obtained in the presence of a 20-fold excess of unlabeled LDL.
The effect of IgG-C7 (0.35 mg/1) was determined as described for lymphocyte binding studies. Data are expressed as nanograms of 125 I-LDL degraded in 4 hours per milligram of total cell protein.
Fibroblast Binding Studies
Cultured human skin fibroblasts were grown and maintained in a humidified 5% CO 2 incubator at 37°C in 75-cm 2 flasks containing 20 ml MEM supplemented with 10% (vol/vol) FCS, penicillin (100 units/ml), streptomycin (100 Mg/ml)> 24 mM NaHCO 3 ,1 mM pyruvate, and 2 mM L-glutamine. For all experiments, confluent cells were detached with a trypsin-EDTA solution, and approximately 5x10" cells were plated in 35-mm wells containing 2 ml growth medium. On day 3 the medium was replaced with fresh medium, and on day 6 confluent cells were incubated in LPDS (2 ml fresh medium containing 5% [vol/vol] LPDS instead of FCS) for 24 hours. After that the cell monolayers were placed for 30 minutes in a 4°C cold room. The medium was then removed, and the cells were incubated for 2 hours at 4°C with 1 ml of ice-cold MEM containing 10 mM HEPES, 5% LPDS, and the indicated amounts of 125 I-LDL and native LDL. After incubation, the cells were washed three times with 3 ml of 50 mM Tris-HCl buffer, pH 7.4, containing 0.15 M NaCl and 2 g/1 BSA and once with 3 ml of 50 mM Tris-HCl buffer, pH 7.4, containing only 150 mM NaCl. Finally, the high-affinity specific binding was measured as described by Brown and Goldstein. 34 Briefly, cells were lysed by incubation in 1 ml 0.5N NaOH overnight. Aliquots (0.5 ml) were removed from each dish, and both the radioactivity (by gamma counter) and the protein concentration 21 were determined. Results are expressed as nanograms of I-LDL binding was determined according to Beisiegel et al. 35 In short, confluent fibroblasts were incubated for 24 hours with medium containing 5% LPDS and were then preincubated for 1 hour at 4°C with or without 0.35 mg/ml of IgG-C7. The high-affinity binding was then measured.
Statistical Analysis
The results are expressed as mean±SEM. Differences between means were compared by Student's t test, with p< 0.05 considered significant.
Results
Properties of 125 I-LDL Binding to Human Platelets
Saturation studies. Figure 1 shows the results of a typical experiment of Labelled LDL (g protein/I) from seven independent experiments, was saturated at a protein concentration of 0.30±0.10 g/1. A Scatchard plot of the data gave a linear correlation coefficient of r=-0.96 (Figure 1, inset) . With an assumed molecular weight for apoB-100 of 550 kd, the number of binding sites per platelet (mean±SEM, n=l) was 1,348±126, with a K D of 50.7±9 nM (27.9±5 jug/ml).
Kinetic studies. The interaction of LDL with platelets was assessed at various periods of time. As shown in Figure 2A the binding was rapid, and apparent equilibrium was reached after incubation for 25 minutes at 22°C. The observed rate constant (K ob ) for the association reaction, obtained by measuring the slope of the plot shown in Figure 2B , was 2.8xlO~3xsec~1. As noted in Figure 2A Figure 2C ). The second-order-association rate constant (K +1 ), calculated from the following equation Effects of temperature and cations. The specific binding curves at 4°C and 37°C were similar to those obtained at 22°C. In three independent experiments (mean±SEM), the number of binding sites (l,350±210 and l,420±320) and the K D (48±5 nM and 53±8 nM) at 4°C and 37°C, respectively, were similar to those at room temperature (1,348±126 and 50±9 nM). The effect of divalent ions on the binding of 125 I-LDL (0.05 g/l) is displayed in Table 1 . Addition of EDTA (up to 20 mM), Ca 2+ (up to 2 mM), or Mg 2+ (up to 1 mM) to the incubation medium had no effect on the binding.
Effect of PGE h In the present study, we investigated the effect of PGEi on LDL binding to washed platelets. No significant differences were obtained when the binding was performed in platelet supensions washed with PGE! (5.6 fiM; results not shown). Recently, it has been demonstrated that PGE! is capable of increasing the binding of LDL to human, rat, and swine liver apoB.E receptors in a dose-dependent manner. 36 The presence of PGEi (100 fiM) in the incubation medium had no stimulatory effect on 
Displacement studies.
Competition experiments were performed to obtain information about the specificity of the recognition of the LDL binding sites in platelets. Table 2 shows that the specificity was not typical of the classical LDL receptor of nucleated cells. Unlabeled lipoproteins competed with 
Effect of Cholesterol Loading on Platelet Composition and I25 I-LDL Binding to Platelets
The content of cholesterol in platelets after incubation with 500 or 1,000 ^g/ml cholesterol was 2.4±0.22 or 5.2±0.41 /ig per 10 8 platelets, respectively. These values were significantly different (/?<0.001) from those obtained in controls without cholesterol (0.34±0.09). The results are mean±SEM of three experiments per triplicate.
It has been reported 37 that in response to cholesterol enrichment, several types of cultured cells undergo a marked decrease in LDL binding (downregulation). To find out whether receptor regulation (up or down) of the platelet binding sites occurs, we studied the effect of cholesterol loading on 1-3) IgG, immunoglobulin G; LDL, low density lipoprotein. Fibroblasts incubated for 24 hours with 5% lipoprotein-deficient serum, sedimented nonadherent lymphocytes (8xlO 6 ), and washed platelets (lxlO 8 ) were prepared as described in "Methods." Cells were preincubated for 1 hour at 4°C (fibroblasts) and for 10 minutes at room temperature (lymphocytes and platelets) with or without 0.35 mg/1 (fibroblasts and lymphocytes) and 5 mg/1 (platelets) of IgG-C7. Then Cholesterol loading of platelets was achieved under incubation conditions that delivered sterol into platelets by a receptor-independent process. Platelets incubated with or without cholesterol presented similar LDL binding properties for B max and K D values, indicating that, in contrast to the classical LDL receptor, no changes in the receptor regulation occurred in platelets.
Competition Experiments Between I25 I-LDL and Monoclonal Antibody IgG-C7 Against the LDL Receptor
Results of competition binding assays to lymphocytes, nbroblasts, and platelets between I25 I-LDL (0.01, 0.03, and 0.05 g of protein per liter) and IgG-C7 (0.35 mg/1 for lymphocytes and fibroblasts and 5 mg/1 for platelets) are shown in Table 3 . Binding of 125 I-LDL to lymphocytes, fibroblasts, and platelets was inhibited by this monoclonal antibody to 88%, 85%, and 5%, respectively (average of the blocking effect of five experiments per duplicate). Moreover, proteolytic degradation of labeled LDL (0.01 g of protein per liter) by lymphocytes was also inhibited to 85±10% (mean±SEM, n=5) by the IgG-C7. In contrast, Figure 3 shows that at concentrations up to 150 mg/1, IgG-C7 was not an effective competitor with 125 I-LDL for LDL binding sites on platelets, and only 5% inhibition was obtained. In parallel, a dose-dependent inhibition was observed in the presence of unlabeled LDL.
Properties of 125 I-LDL Binding to Platelets From Patients With Familial Hypercholesterolemia
To establish whether genetic abnormalities of the LDL receptor of nucleated cells perturb LDL binding to Table 4 shows data on the in vitro sensitivity of platelets to aggregating agents in the absence and presence of LDL (0.5 g of protein per liter). In agreement with previous reports, 6 -8 LDL sensitized the platelets and significantly increased the percentage of platelet aggregation in response to low concentrations of ADP or collagen. The preincubation of IgG-C7 (150 mg/1) for 10 minutes with washed platelets before the addition of LDL did not produce an inhibitory effect on the enhanced sensitivity of platelets to ADP or collagen induced by LDL. In fact, the LDL-induced platelet aggregation by ADP (1 and 2 /xM) and collagen (1 jug/ml) was similar in the absence (60±7%, 81±8%, and 72±6%, respectively) or presence (65±5%, 80±8%, and 74±5%, respectively) of IgG-C7. Moreover, the interaction of IgG-C7 with LDL binding sites in platelets was assessed at various preincubation periods of time (10 and 30 minutes) and temperature (4°C, 22°C, and 37°C) before the addition of LDL and ADP or collagen. With our experimental conditions, IgG-C7 was unable to block 125 I-LDL binding to platelets (Table 4) .
Aggregation Studies
Discussion
The aim of this study was to investigate possible differences between LDL binding sites on platelets and the described LDL receptor of nucleated cells. To achieve this, different approaches such as a complete characterization of binding, the use of platelets from patients with a genetic disorder for the classical LDL receptor, and the capability of LDL to enhance agonistinduced platelet aggregation were used.
Saturation studies showed that washed human platelets bound 125 I-LDL to saturable binding sites, numbering about 1,348 per platelet, and the K D was 50±9 nM. When we determined the rate constants for association (/C +1 ) and dissociation (K^i), the equilibrium dissociation constant K D was 55 nM. If the 125 I-LDL binding reaction obeys the mass-action law, then the dissociation constants of kinetic, displacement, and saturation studies should be equal. We have found a K D of 55 and 45 nM in kinetic and displacement experiments, respectively. These results are in reasonable agreement with the data obtained by saturation studies, so we can affirm that the 125 I-LDL binding to platelets obeys the massaction law. Furthermore, the 125 I-LDL binding to platelets was rapid and reversible, and an apparent equilibrium was attained within 25 minutes at 22°C; it was unaltered by temperature and either divalent cations or chelating agents. These results were similar to those previously reported, 101113 except for one study 14 that described that LDL binding to platelets was dependent on time and temperature. A change in receptor regulation (up or down) was observed neither when platelets were loaded with cholesterol nor when they were incubated in the presence of PGE, (100 fiM). In contrast, it is well known that LDL 1) binds to nucleated cells with a 10-fold higher affinity (K D =5 nM), 2) reaches apparent equilibrium within 5 hours at 4°C, 3) is clearly temperature dependent, and 4) is sensitive to calcium depletion and that cholesterol loading produces a downregulation of the LDL receptor 23 and PGE, enhances LDL binding to the liver LDL receptor. 36 In addition, displacement experiments showed that the specificity of LDL binding sites on platelets was strongly different from those previously demonstrated for the LDL receptor of nucleated cells. The displacement of 125 I-LDL (0.05 g/l) showed that the interaction between unlabeled and labeled LDL presented the same affinity (IC 50 of 0.04 g/l, with a K D of 25 /xg/ml, or 45 nM) with a Hill constant of -1.04, indicating that the displacement was competitive at a single set of binding sites. Moreover, the displacement caused by HDL is only related to the HDL 2 subpopulation (IC 50 of 0.60 g/l, with a K D of 204.15 )ag/ml), and this agrees with the inhibitory effect attributed to the apoE-rich HDL subfraction reported by Hassall et al. 15 The Hill constant for HDL 2 was -1.09, suggesting that the displacement was similar to that obtained with unlabeled LDL. Interestingly, VLDL (IC 5 o of 0.15 g/l, with a K D of 62.05 ji.g/ml) was a potent inhibitor of 125 I-LDL binding. The Hill constant for VLDL was -0.79, indicating that either negative cooperation or multiple binding sites are involved in the interaction of the two ligands. This effect has not been described in nucleated cells, where VLDL binds poorly to LDL receptors. 38 On the other hand, we found a considerable inhibitory effect of IDL (IC 50 of the LDL receptor to characterize the binding sites for LDL on platelets. The ability of IgG-C7 to determine and identify the LDL receptor of human fibroblasts has been described. 193539 IgG-C7 blocked the binding, uptake, and degradation of LDL in fibroblasts and allowed recognition of the function of the first cysteine-rich repeat in the ligand-binding domain of the LDL receptor, which is to bind Ca 2+ but not lipoproteins. 19 ' 3539 We confirmed that 125 I-LDL binding to fibroblasts was inhibited by IgG-C7, whereas in lymphocytes inhibition (not described) of 125 I-LDL binding and 125 I-LDL proteolytic degradation was observed. This fact reconfirmed the utility of this monoclonal antibody in studies of the classical LDL receptor. However, under the same experimental conditions as used for lymphocytes, we were unable to obtain a blocking effect on 125 I-LDL binding to platelets by this monoclonal antibody, even at a 400-fold excess (compared with lymphocytes and fibroblasts). The properties described above for LDL binding to platelets support the notion that LDL binds to platelets by high-affinity and saturable sites, which differ from those described in nucleated cells and is probably under different genetic control.
To obtain more evidence, we studied the existence of specific and saturable LDL sites in platelets from patients with a total (homozygote) or partial (heterozygote) defect of LDL receptors. Our results confirm that platelets from these patients bind 125 I-LDL with binding characteristics similar to those obtained in platelets of healthy volunteers. This fact reinforced the existence of specific and saturable LDL sites in platelets from FH patients and agrees with those reported by others. 1840 Finally, we studied the capability of LDL to enhance ADP-and collagen-induced platelet aggregation and the possible blocking effect of IgG-C7 on this biological response. There is some evidence indicating that the interaction of LDL with its specific binding sites causes LDL-induced sensitization of platelets, probably through recognition of the positively charged arginine and lysine residues of the apoB of LDL.
18 ' 40 In agreement with other studies 6 -8 reporting that plasma lipoproteins can modulate the reactivity of human platelets, we observed that LDL at a protein concentration of 0.5 g/1 enhanced platelet reactivity to aggregating agents, such as ADP and collagen. In parallel with this and in accordance with the results described by Beitz et al, 8 thromboxane A 2 production and ATP release were increased (results not shown). It has been suggested that an enhanced intracellular cholesterol level is responsible for increased platelet aggregation. 102941 Moreover, the role of the classical LDL receptor on the homeostasis of intracellular cholesterol is well known. With consideration of these facts, the monoclonal antibody used should completely inhibit cholesterol uptake and therefore platelet aggregation. However, under our experimental conditions we found the lack of a blocking effect by IgG-C7 on the LDL-induced agonist platelet sensitization.
In summary, the binding properties, the existence of 125 I-LDL binding in platelets from FH patients, and especially the lack of a blocking effect by IgG-C7 on l-LDL binding and also on LDL-induced platelet reactivity support the hypothesis that human platelets bind LDL by a receptor different from the classical LDL receptor of nucleated cells.
